Patents by Inventor Elaine A Delack
Elaine A Delack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9364474Abstract: A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered topically or transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day. In homeopathic use, the reserpine may be administered in the form of a homeopathic dilution, preferably as a 12 C homeopathic dilution of reserpine.Type: GrantFiled: May 14, 2013Date of Patent: June 14, 2016Assignee: MedDEV Inc.Inventor: Elaine A. DeLack
-
Publication number: 20140018382Abstract: A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered topically or transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day. In homeopathic use, the reserpine may be administered in the form of a homeopathic dilution, preferably as a 12 C homeopathic dilution of reserpine.Type: ApplicationFiled: May 14, 2013Publication date: January 16, 2014Applicant: MedDEV, Inc.Inventor: Elaine A. DeLack
-
Patent number: 8440685Abstract: A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered topically or transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day.Type: GrantFiled: January 12, 2010Date of Patent: May 14, 2013Assignee: MedDEV, Inc.Inventor: Elaine A. DeLack
-
Patent number: 8314136Abstract: A method for treating Alzheimer's Disease (AD) or Autism Spectrum Disorder (ASD) by administering at least one alky ester of imidazolecarboxylc acid, preferably methyl 4-imidazolecarboxylate. It is hypothesized that the treatment counters AD/ASD by maintaining the intracellular/extracellular osmolyte gradient in the central nervous system (CNS) within a substantially normal range. The methyl 4-imidazolecarboxylate may be administered orally, by inhaler, by injection or by transdermal application. When administered by transdermal application, the dosage range may be from about 0.01 mcg per day to about 3.0 mcg per day, preferably from about 0.1 mcg per day to about 0.3 mcg per day.Type: GrantFiled: February 23, 2010Date of Patent: November 20, 2012Assignee: MedDEV, Inc.Inventor: Elaine A. DeLack
-
Patent number: 8211872Abstract: A method for treating the symptoms of multiple sclerosis and related neurodegenerative conditions, using a histamine compound that is methylated in vitro prior to being introduced into the body of the patient. The histamine compound is suitably histamine diphosphate, and may be methylated in vitro by mixing in combination with at least one thiol compound in the presence of at least one methyl group donor compound. The thiol compound is suitably L-reduced glutathione and the methyl group donor is suitably betaine hydrochloride. The compounds are mixed vigorous in an acid environment, to create a shearing force that facilitates exchange of the methyl group from the donor compound to the histamine diphosphate. The resulting methylated histamine compound is suitably administered to the patient by transdermal application. The method also provides a medicament for treatment the symptoms of multiple sclerosis and related neurodegenerative conditions, and a method for preparation of such a medicament.Type: GrantFiled: October 24, 2008Date of Patent: July 3, 2012Assignee: MedDEV, Inc.Inventor: Elaine A. Delack
-
Patent number: 7666893Abstract: A method for treatment of multiple sclerosis and other neurodegenerative diseases, disorders or conditions. An alkyl ester of imidazole carboxylic acid, preferably methyl 4-imidazolecarboxylate, is administered in a therapeutic amount. It is hypothesized that the alkyl ester of imidazole carboxylic acid serves to restore and/or maintain the intracellular/extracellular osmolyte gradient in the central nervous system (CNS). The methyl 4-imidazolecarboxylate may be administered transdermally, using PLO gel or other suitable transdermal carrier. The compound may also be administered orally, inhaler or by injection. The treatment is advantageously performed on a three day cycle, with a period of two days intervening between each day on which the compound is administered. Dosage ranges may be from about 0.01 mcg to about 3.0 mcg, with dosages in the range from about 0.1 mcg to about 0.2 mcg in generally preferred when using transdermal administration.Type: GrantFiled: May 23, 2007Date of Patent: February 23, 2010Assignee: MedDEV Inc.Inventor: Elaine A. Delack
-
Patent number: 7645766Abstract: A method for treatment of depression and depressive mood disorders. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A, so as to increase synaptic metabolism of serotonin to 5-HIAL. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day. A caffeine compound may be administered simultaneously so as to compensate for an antihypertensive effect of the reserpine. The caffeine compound may be combined with the reserpine in a transdermal cream.Type: GrantFiled: September 20, 2005Date of Patent: January 12, 2010Assignee: MedDEV, Inc.Inventor: Elaine A. Delack
-
Publication number: 20080003209Abstract: A method for treatment of neurodegenerative disease conditions stemming from multiple sclerosis, aging, autoimmune diseases and fibromyalgia. A compound effective to increase neuronal metabolism of histamine to a histamine H2 agonist is administered in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain myelin against undergoing self-degeneration. The compound is selected from the group consisting of histamine M-methyltransferase, monoamineoxidase-A, monoamineoxidase-A agonists and histamine H3 antagonists. The histamine M-methyltransferase may be administered to increase neuronal metabolism of histamine to tele-methylhistamine, whereas the monoamineoxidase-A or monoamineoxidase-A agonist may be administered so as to increase neuronal metabolism of telemethylhistamine to an H2 agonist.Type: ApplicationFiled: June 19, 2007Publication date: January 3, 2008Inventor: Elaine Delack
-
Publication number: 20070276021Abstract: A method for treatment of multiple sclerosis and other neurodegenerative diseases, disorders or conditions. An alkyl ester of imidazole carboxylic acid, preferably methyl 4-imidazolecarboxylate, is administered in a therapeutic amount. It is hypothesized that the alkyl ester of imidazole carboxylic acid serves to restore and/or maintain the intracellular/extracellular osmolyte gradient in the central nervous system (CNS). The methyl 4-imidazolecarboxylate may be administered transdermally, using PLO gel or other suitable transderamal carrier. The compound may also be administered orally, inhaler or by injection. The treatment is advantageously performed on a three day cycle, with a period of two days intervening between each day on which the compound is administered. Dosage ranges may be from about 0.01 mcg to about 3.0 mcg, with dosages in the range from about 0.1 mcg to about 0.2 mcg in generally preferred when using transdermal administration.Type: ApplicationFiled: May 23, 2007Publication date: November 29, 2007Inventor: Elaine A. Delack
-
Patent number: 7232830Abstract: A method for treatment of neurodegenerative disease conditions stemming from multiple sclerosis, aging, autoimmune diseases and fibromyalgia. A compound effective to increase neuronal metabolism of histamine to a histamine H2 agonist is administered in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain myelin against undergoing self-degeneration. The compound is selected from the group consisting of histamine M-methyltransferase, monoamineoxidase-A, monoamineoxidase-A agonists and histamine H3 antagonists. The histamine M-methyltransferase may be administered to increase neuronal metabolism of histamine to tele-methylhistamine, whereas the monoamineoxidase-A or monoamineoxidase-A agonist may be administered so as to increase neuronal metabolism of telemethylhistamine to an H2 agonist.Type: GrantFiled: June 21, 2001Date of Patent: June 19, 2007Inventor: Elaine A Delack
-
Publication number: 20030113309Abstract: A method for treatment of neurodegenerative disease conditions stemming from multiple sclerosis, aging, autoimmune diseases and fibromyalgia. A compound effective to increase neuronal metabolism of histamine to a histamine H2 agonist is administered in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain myelin against undergoing self-degeneration. The compound is selected from the group consisting of histamine M-methyltransferase, monoamineoxidase-A, monoamineoxidase-A agonists and histamine H3 antagonists. The histamine M-methyltransferase may be administered to increase neuronal metabolism of histamine to tele-methylhistamine, whereas the monoamineoxidase-A or monoamineoxidase-A agonist may be administered so as to increase neuronal metabolism of telemethylhistamine to an H2 agonist.Type: ApplicationFiled: June 21, 2001Publication date: June 19, 2003Inventor: Elaine A. Delack